As early as in the 19th century, pathologic studies reported the perivenous distribution of MS lesions.^[@R1]^ The cascade of lesion development includes activation of T lymphocytes, attachment to the endothelium with subsequent migration through the vessel walls into the perivascular space, and local activation of a cascade of immune responses.^[@R2],[@R3]^ Postmortem studies demonstrated that the venous diameter is significantly narrowed in MS lesions as a consequence of perivascular cuffing, fibrosis, and collagen deposition.^[@R4],[@R5]^

Susceptibility-weighted imaging (SWI) is an emerging MRI technique that can visualize the cerebral venous architecture because of its sensitivity to the presence of deoxyhemoglobin.^[@R6]^ While various MRI studies have demonstrated that penetrating veins can be detected in most MS lesions,^[@R7][@R8][@R9]^ only a few cross-sectional MRI studies have reported a decreased venous diameter in MS lesions in a quantitative manner.^[@R10],[@R11]^ We investigated the spatiotemporal evolution of the venous appearance in acute MS lesions in a longitudinal fashion, analyzing the venous diameter before, during, and after contrast enhancement in serial MRI data.

Methods {#s1}
=======

From our prospectively collected database, we retrospectively screened patients with relapsing-remitting MS being at least 18 years of age who were investigated with serial 3T MRI for the presence of supratentorial acute contrast-enhancing lesions with at least one MRI examination before contrast enhancement. To minimize partial volume effects, only lesions with a minimum diameter of 5 mm on axial slices were included. Infratentorial lesions were excluded because of limited visualization of veins and image artifacts. Exclusion criteria were presence of neurologic conditions other than MS and missing or unsatisfactory MRI (e.g., due to motion artifacts).

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

This study was approved by the local ethics committee (2017-830R-MA); patient consent was waived because of the retrospective nature of the study and the lack of patient interaction.

MRI {#s1-2}
---

All MRI studies were conducted on a 3.0T MR system (MAGNETOM Skyra; Siemens, Erlangen, Germany, 20-channel head coil, 50-cm field of view \[FOV\]). The standardized protocol included a high-resolution 3D magnetization-prepared rapid acquisition gradient-echo sequence (echo time \[TE\] = 2.49 ms, repetition time \[TR\] = 1,900 milliseconds, inversion time \[TI\] = 900 milliseconds, FOV 240 × 240 mm^2^, and spatial resolution = 0.9 × 0.9 × 0.9 mm^3^) and a 3D fluid-attenuated inversion recovery (FLAIR) data set (TE = 398 milliseconds, TR = 5,000 milliseconds, TI = 1,800 milliseconds, FOV 240 × 240 mm^2^, and resolution = 0.5 × 0.5 × 0.9 mm^3^). SWIs (TR = 27 milliseconds, TE = 20 milliseconds, FOV = 220 mm, slice thickness = 1.5 mm, and voxel size = 0.9 × 0.9 × 1.5 mm) were acquired after injection of gadoterate meglumine at a standard dose of 0.1 mmol/kg, which was followed by T1-weighted images (TR = 225 milliseconds/TE = 2.5 milliseconds, FOV = 220 mm, slice thickness = 3 mm, and voxel size = 0.7 × 0.7 × 3.0 mm).

Data processing and analysis {#s1-3}
----------------------------

Image postprocessing was performed offline. To facilitate analysis, FLAIR and postcontrast T1-weighted images were coregistered onto the SWIs ("FLAIR/SWIs" and "T1-Gd/SWIs") using the automated FLIRT (FMRIB\'s Linear Image Registration Tool), part of FSL (FMRIB\'s Software Library) (version 5.0.2.1; <http://fsl.fmrib.ox.ac.uk/fsl/>).^[@R12],[@R13]^ Two neurologists with extensive experience in MS imaging (P.E. and A.G.) evaluated all MR images jointly. Readers were unaware of the clinical information. Postcontrast T1-weighted images were investigated for supratentorial acute contrast-enhancing parenchymal lesions. The time point of acute contrast enhancement was defined as *t* = 0. MRI examinations before contrast enhancement were defined as *t* = −1, *t* = −2, etc. and follow-up examinations analogous as *t* = +1, *t* = +2, etc. According to their topography, lesions were classified as periventricular (attached to the walls of the ventricles), paraventricular (located ≤3 mm next to the ventricles), subcortical (located \>3 mm next to the ventricles), or juxtacortical (attached to the cortex). After lesion identification on postcontrast T1-weighted images, coregistered FLAIR/SWIs and T1-Gd/SWIs were investigated. For every lesion, the presence of a central vein was analyzed. Veins were classified as "deep" (draining into the deep cerebral venous system) or "superficial" (draining into the subarachnoid space) as proposed previously.^[@R14]^ Prior and follow-up MRI examinations were evaluated for the presence of the corresponding vein. In addition, in every patient, 4 randomly selected supratentorial veins in the normal-appearing brain tissue that were detectable throughout all MRI examinations were investigated. Calculation of the venous diameter for each time point was performed as described previously.^[@R10]^ In short, seed points were placed at the center of each vein on axial slices. The seed points were aligned offline, and the reconstructed vein was displayed in a single reconstructed plane. Venous diameters were measured in 2 different locations, whereas 1 measurement was taken at the largest diameter and 1 at the smallest. The 2 measurements were averaged to obtain the mean diameter of each vein and used for statistical analysis.

Statistical analysis {#s1-4}
--------------------

Statistical analysis was performed with IBM SPSS Statistics Version 22. A paired *t* test was used to compare the venous diameter between *t* = 0, *t* = −1, and *t* = +1, as well as to compare *t* = −1 and *t* = +1. Because only a small number of veins had more than 1 prior or follow-up MRI examination, no further statistical analysis was performed between these time points. Unless otherwise noted, all results are reported as mean ± SD.

Results {#s2}
=======

Overall, we identified 70 patients with MS who were investigated with serial MRI including SWI. In 52/70 patients with MS, no contrast-enhancing lesions were detectable; these patients were excluded. In the remaining 18 patients with relapsing-remitting MS (7 men and 11 women, mean age 33 ± 10 years, median Expanded Disability Status Scale score 2 ± 1.5, mean disease duration 1.5 ± 1.5 years) with at least 1 prior 3T MRI examination including SWI (range 1--3 prior MRI examinations), we identified a total of 54 acute contrast-enhancing lesions. Fifteen of 18 patients were on best individually selected treatment with natalizumab (n = 2), fingolimod (n = 2), dimethyl fumarate (n = 8), or interferon-β (n = 3). In 14/54 (26%) lesions, no central vein was visible on SWI; these lesions were excluded. The remaining 40 (74%) lesions were included for further analysis. In 29/40 cases, at least 1 follow-up (range 1--4) 3T MRI examination was available, resulting in a total of 166 MRI examinations. Ten of 40 (25%) lesions were classified as periventricular, 8/40 (20%) as paraventricular, 16/40 (40%) as subcortical, and 6/40 (15%) as juxtacortical lesions. Twenty-four of 40 (60%) veins were classified as "deep" and 16/40 as "superficial." The mean intervals between MRI examinations were as follows: *t* = −1: 7 months prior contrast enhancement (range 1--30 months), *t* = −2: 15 months prior contrast enhancement (range 4--30 months), *t* = −3: 21 months prior contrast enhancement (range 8--35 months), *t* = +1: 5.5 months after contrast enhancement (range 3--14 months), *t* = +2: 10 months after contrast enhancement (range 4--20 months), and *t* = +3: 19 months after contrast enhancement (range 15--26 months).

The mean venous diameters for all time points are presented in [table](#T1){ref-type="table"}. The mean intralesional venous diameter was smaller at the time of acute contrast enhancement (0.80 ± 0.12 mm) than before (1.16 ± 0.19 mm; *p* \< 0.001) and after contrast enhancement (1.07 ± 0.15 mm; *p* \< 0.001). The mean venous diameter was still smaller on follow-up examinations after contrast enhancement had seized (1.07 ± 0.15 mm) when compared with the venous diameter before contrast enhancement (1.16 ± 0.19 mm; *p* = 0.021). However, the mean venous diameter of extralesional veins located in the normal-appearing brain tissue (*t* = 0: 1.13 ± 0.11 mm, *t* = −1: 1.11 ± 0.14 mm, and *t* = +1: 1.12 ± 0.16 mm) did not statistically differ between MRI examinations (*p* \> 0.05 for all comparisons). [Figure 1](#F1){ref-type="fig"} shows a box plot of the venous diameter of 7 MRI examinations in chronological order. [Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} demonstrate examples of venous narrowing at the time of acute contrast enhancement.

###### 

Characteristics of intralesional veins
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![Box plot of the venous diameter in lesions\
Box plot of the venous diameter of 7 MRI examinations in chronological order. X-axis: relative time points for comparison with *t* = 0, range of intervals as given below in months (m). The number of analyzed veins (n) is given below. Y-axis: venous diameter (mm).](NEURIMMINFL2017013938f1){#F1}

![Example of venous narrowing\
Exemplary serial MRI examinations in a 34-year-old man with relapsing-remitting MS (disease duration at the time of acute contrast enhancement: 4 years, Expanded Disability Status Scale score: 2.5). (A) Postcontrast T1-weighted images demonstrate an acute contrast-enhancing lesion (*t* = 0; white arrowhead). (B) The lesion is prominently hyperintense on fluid-attenuated inversion recovery (FLAIR) images. Coregistered FLAIR-/susceptibility-weighted images (SWIs) (C) and magnified SWIs (D) demonstrate the central vein (dotted arrow; *t* = 0). At the time of contrast enhancement (*t* = 0), the venous diameter is significantly smaller (0.85 mm) compared with the MRI examination before contrast enhancement (*t* = −19 months; venous diameter: 1.3 mm) and after contrast enhancement (*t* = +6 months; venous diameter: 1.0 mm; white arrows).](NEURIMMINFL2017013938f2){#F2}

![Example of venous narrowing\
Exemplary serial MRI examinations in a 41-year-old woman with relapsing-remitting MS (disease duration at the time of acute contrast enhancement: 5 years, Expanded Disability Status Scale score: 3.5). (A) Postcontrast T1-weighted images demonstrate an acute contrast-enhancing lesion (*t* = 0; white arrowhead). (B) The lesion is prominently hyperintense on fluid-attenuated inversion recovery images. Susceptibility-weighted images (C) and magnification (D) demonstrate the central vein (red arrow; *t* = 0). At the time of contrast enhancement, the venous diameter is significantly smaller (0.7 mm) compared with the MRI examination before contrast enhancement (*t* = −12 months; venous diameter: 1.1 mm, white arrow).](NEURIMMINFL2017013938f3){#F3}

Discussion {#s3}
==========

There has been an increasing interest in the fine structure of MS lesions because MS studies at 7T repeatedly demonstrated veins in the center of MS lesions.^[@R9],[@R11],[@R15]^ This pathologically well-known feature of MS lesions was also seen and confirmed in experimental autoimmune encephalomyelitis.^[@R14]^ In addition, a recent study demonstrated that the venous diameter is significantly smaller in MS lesions when compared with the diameter of extralesional veins on gradient-echo T2\* MRI.^[@R10]^ Our results in the present study are very much in line with those findings in that we also identified central veins in the majority of acute contrast-enhancing lesions and that there is apparently venous narrowing detectable in acute contrast-enhancing MS lesions when compared with the venous diameter before blood-brain barrier breakdown. These findings are of interest for several reasons.

Our study was performed on a clinical 3T MRI system using commercially available sequences and postprocessing techniques. This study demonstrates that there is a good chance to detect veins in contrast-enhancing lesions (74% in this data set), as it has been demonstrated repeatedly before for T2 hyperintense lesions. The combination of contrast enhancement and the visualization of a central vein may well increase the specificity of MRI in MS. This will need to be further explored in larger prospective studies.

Although a recent expert panel remained conservative in regard to the inclusion of the demonstration of central veins to the diagnostic criteria of MS,^[@R16]^ there appears to be increasing evidence on the differential diagnostic value of such findings, which may well fit into the picture of a suspected MS.^[@R17],[@R18]^ A contrast-enhancing lesion with a central vein may well increase the diagnostic certainty.

The more is known about the underlying pathophysiologic mechanisms in focal lesions, the easier it may become in the future to determine the characteristic pathology. In this regard, the finding of narrowing of veins is of interest. One may consider several possible explanations for this phenomenon.

SWI, a velocity-corrected 3-dimensional gradient-echo sequence,^[@R19]^ is a blood-oxygen-level-dependent emerging MRI technique that visualizes changes in magnetic susceptibility caused by different paramagnetic substances.^[@R20]^ Because of its sensitivity to deoxyhemoglobin, SWI has the potential to demonstrate both changes in brain oxygen metabolism and venous architecture. In acute ischemic stroke, a relative increase in the deoxyhemoglobin level caused by an imbalance between oxygen supply and demand in hypoperfused areas results in a prominent hypointense signal in the draining veins on SWI,^[@R21],[@R22]^ whereas in status epilepticus, reduced venous signals due to increased levels of oxygenated hemoglobin as a consequence of an increased demand with corresponding hyperperfusion have been reported.^[@R23],[@R24]^ In MS, dynamic susceptibility contrast perfusion studies have reported signs of increased perfusion in acute contrast-enhancing lesions compared with the normal-appearing white matter.^[@R25],[@R26]^ In one study, the authors suggest that increased perfusion was detectable even before contrast enhancement.^[@R27]^ Theoretically, increased levels of oxygenated hemoglobin due to an increased metabolic demand in acute contrast-enhancing lesions could result in reduced venous signal on SWI, and a previous study reported reduced visibility of periventricular white matter veins in patients with MS compared with healthy controls.^[@R28]^

More direct morphologic evidence of venous narrowing has been demonstrated in histopathologic MS studies of subcortical white matter lesions in which inflammation around small veins are commonly found.^[@R29],[@R30]^ Perivascular inflammation consisting of inflammatory cells, fibrinoid, exudate, and perivenous iron deposition within and around the vessel wall forms a perivascular cuff.^[@R4],[@R5]^ In addition to the edematous accumulation of interstitial fluid due to blood-brain barrier permeability changes, tissue swelling of contrast-enhancing lesions might cause compression of intralesional veins. In acute MS lesions, a dense infiltration of macrophages and T lymphocytes in the white matter and in small vessels has been described, which could contribute to venous luminal narrowing.^[@R31][@R32][@R33]^ In chronic lesions, venous narrowing is thought to represent a consequence of intimal hyperplasia, fibrosis, and collagenous thickening.^[@R4],[@R10]^ Our results are in line with these findings as we observed significantly decreased venous diameters at the time of acute blood-brain barrier breakdown and contrast enhancement. On follow-up examinations, the mean venous diameter showed a partial recovery but still remained significantly smaller compared with the diameter before contrast enhancement. One might hypothesize that venous narrowing in acute contrast-enhancing lesions is at least partially related to a structural phenomenon before repair and degenerative mechanisms in chronic lesions set in.

However, this study is not without limitations: This was a retrospective study, and the sample size was relatively small. Future longitudinal studies including more patients may consolidate our findings. To describe the fine detail of lesions and veins, high image resolution and exact repositioning are very important to describe the venous detail, and this was performed very carefully, as it is such an important element of follow-up studies. The longitudinal study approach when patients serve as their own control may further underline the validity of the measurements. Certainly, this is an initial and preliminary observation in a serial study, which will need further confirmation with a dedicated higher resolution MRI protocol and/or serial 7T study. Another limitation is that SWI data sets were acquired after gadolinium administration, and therefore, the extent of venous narrowing might be underestimated in our study because gadolinium shortens T1 relaxation and might enlarge hypointense vessels on SWI as a consequence of a "blooming effect." Furthermore, blood-brain barrier breakdown at the time of contrast enhancement and leakage of gadolinium might result in venous enlargement. We found the smallest venous diameter at the time point of acute contrast enhancement, and therefore, we think it is unlikely that these observations might have influenced our results. Indeed, the mean diameters of intralesional veins in our study are very much comparable with the diameter obtained by another group that has used slightly different data acquisition strategies for the assessments in their patients.^[@R10]^ Further technical improvement and more detailed anatomical visualization using 7T MRI or other approaches should explore venous narrowing in acute MS lesions in the future.

Our data demonstrate that the diameter of veins in MS lesions is significantly smaller at the time point of blood-brain barrier breakdown compared with that at time points before and after acute contrast enhancement. Therefore, our findings contribute to the extending knowledge of spatiotemporal plaque development and evolution.
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